Abstract

Glycoprotein IIb/IIIa inhibitors: (a) True; (b) False; (c) True; (d) False; (e) False (a) GP IIb/IIIa inhibitors block fibrinogen cross-links between platelets. (b,c) They are not licensed with thrombolysis but have a role in stenting during PTCA. (e) There is no specific reversal therapy available. response. (c) Naloxone is a competitive antagonist. There is no evidence for agonist activity. (d) This a characteristic of a competitive antagonist. (e) Naloxone will reverse the effects of full, partial and inverse agonists. 135. 129. The troponins: (a) True; (b) True; (c) False; (d) False; (e) True (a) Elevated serum troponins may reflect an area of myocardial necrosis weighing < 1.0 g. (b) Troponins may remain elevated for up to 10 days. (c) This may reflect incomplete apoptosis as part of a non-ischaemic inflammatory process (e.g. in sepsis). (d) Typically detected at 4--10 h. (e) High TnT is associated with increased mortality in sepsis. Concerning agonists and antagonists: (a) False; (b) False; (c) True; (d) False; (e) False (a) KD is a measure of ligand affinity and is usually obtained in a binding experiment. (b) Efficacy is related to the strength or size of a response produced. (c) EC50 is the concentration